<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772742</url>
  </required_header>
  <id_info>
    <org_study_id>19139A</org_study_id>
    <nct_id>NCT04772742</nct_id>
  </id_info>
  <brief_title>Eptinezumab in Adults With Migraine and Medication Overuse Headache</brief_title>
  <acronym>Sunlight</acronym>
  <official_title>Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine in Patients With a Dual Diagnosis of Migraine and Medication Overuse Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients&#xD;
      with the combined diagnosis of migraine and medication overuse headache&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients planned for randomization: 91 patients in the eptinezumab 100 mg group and 91&#xD;
      patients in the placebo group.&#xD;
&#xD;
      The total study duration from the Screening Visit to the Safety Follow-up Visit is&#xD;
      approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled&#xD;
      Period (12 weeks), an Open-Label Period (12 weeks) and a Safety Follow-up Period (8 weeks).&#xD;
      Patient will receive investigational medicinal product (IMP) at the Baseline Visit with&#xD;
      either eptinezumab or placebo by IV infusion and at week 12 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">September 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the number of monthly migraine days (MMDs)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MMDs with use of acute medication</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥50% reduction from baseline in MMDs</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine rate on the day after dosing</measure>
    <time_frame>At Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥75% reduction from baseline in MMDs</measure>
    <time_frame>Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of monthly headache days (MHDs)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥75% reduction from baseline in MMDs</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥75% reduction from baseline in MHDs</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥75% reduction from baseline in MHDs</measure>
    <time_frame>Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of MHDs with use of acute medication</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rate of migraines with severe pain intensity</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rate of headaches with severe pain intensity</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) score</measure>
    <time_frame>At Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most Bothersome Symptom (MBS) (score as measured relative to Screening)</measure>
    <time_frame>At Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score</measure>
    <time_frame>Baseline to Week 12]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Resources Utilization (HCRU)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Work Productivity and Activity impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Migraine</condition>
  <condition>Medication Overuse Headache</condition>
  <arm_group>
    <arm_group_label>Eptinezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion&#xD;
Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase (at baseline): Placebo by IV infusion&#xD;
Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - solution for infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptinezumab</intervention_name>
    <description>Eptinezumab - 100 mg, solution for infusion</description>
    <arm_group_label>Eptinezumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lu AG09221</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has a diagnosis of migraine as defined by International Headache Society&#xD;
             (IHS) International Classification of Headache Disorders (ICHD)-3 guidelines confirmed&#xD;
             at the Screening Visit with a history of migraine onset of at least 12 months prior to&#xD;
             the Screening Visit.&#xD;
&#xD;
          -  The patient has ≥8 migraine days per month for each month on average within the past 3&#xD;
             months prior to the Screening Visit.&#xD;
&#xD;
          -  The patient has a diagnosis of medication overuse headache (MOH) as defined by IHS&#xD;
             ICHD-3 guidelines.&#xD;
&#xD;
          -  The patient has headache on ≥15 days/month for each month within the past 3 months&#xD;
             prior to the Screening Visit.&#xD;
&#xD;
          -  The patient has regular overuse of one or more drugs that can be taken for acute&#xD;
             and/or symptomatic treatment of headache, for &gt;3 months.&#xD;
&#xD;
          -  The patient has ≥15 to ≤26 headache days, of which ≥8 days were assessed as migraine&#xD;
             days during the Screening Period, based on prospectively collected information in the&#xD;
             eDiary.&#xD;
&#xD;
          -  The patient overuses drugs that can be taken for acute and/or symptomatic treatment of&#xD;
             headache during the Screening Period, based on prospectively collected information in&#xD;
             the eDiary.&#xD;
&#xD;
          -  The patient has demonstrated compliance with the Headache eDiary by entry of data for&#xD;
             at least 24 of the 28 days of the Screening Period.&#xD;
&#xD;
          -  The patient has had an onset of migraine at &lt;50 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has experienced failure on a previous treatment targeting the calcitonin&#xD;
             gene-related peptide (CGRP) pathway.&#xD;
&#xD;
          -  The patient has confounding and clinically significant pain syndromes, (for example,&#xD;
             fibromyalgia, chronic low back pain, complex regional pain syndrome).&#xD;
&#xD;
          -  The patient has a diagnosis of acute or active temporomandibular disorder.&#xD;
&#xD;
          -  The patient has a history or diagnosis of chronic tension-type headache, hypnic&#xD;
             headache, cluster headache, hemicrania continua, new daily persistent headache, or&#xD;
             unusual migraine subtypes such as hemiplegic migraine (sporadic and familial),&#xD;
             recurrent painful ophthalmoplegic neuropathy, migraine with brainstem aura and&#xD;
             migraine with neurological accompaniments that are not typical of migraine aura&#xD;
             (diplopia, altered consciousness, or long duration).&#xD;
&#xD;
          -  Patients with a lifetime history of psychosis, bipolar mania, or dementia are&#xD;
             excluded. Patients with other psychiatric conditions whose symptoms are not controlled&#xD;
             or who have not been adequately treated for a minimum of 6 months prior to screening&#xD;
             are also excluded.&#xD;
&#xD;
          -  The patient has a history of clinically significant cardiovascular disease, including&#xD;
             uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example,&#xD;
             cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).&#xD;
&#xD;
        Other in- and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangxi Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Rizhao</name>
      <address>
        <city>Rizhao</city>
        <zip>276826</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong - Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <zip>518053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Huanhu Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300350</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <zip>325035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pineo Medical Ecosystem</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aversi Clinic LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nowon Eulji Medical Center, Eulji University</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - PPDS</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Georgia</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache Disorders, Secondary</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

